| Id: | acc3179 |
| Group: | 2sens |
| Protein: | JNK |
| Gene Symbol: | MAPK8 |
| Protein Id: | P45983 |
| Protein Name: | MK08_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr185 |
| Site Sequence: | AGTSFMMTPYVVTRYYRAPEV |
| Disease Category: | Eye diseases |
| Disease: | Cataract |
| Disease Subtype: | |
| Disease Cellline: | SRA 01-04 |
| Disease Info: | |
| Drug: | honokiol |
| Drug Info: | "Honokiol is a natural compound with various pharmacological properties, such as anti - inflammatory and anti - cancer effects." |
| Effect: | modulate |
| Effect Info: | "Magnolol blocks H?O?-induced apoptosis of human lens epithelial cells by inhibiting the phosphorylation of ERK1/2, p38 MAPK, JNK, Akt, and NF-κB p65." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 20965163 |
| Sentence Index: | 20965163_5-6 |
| Sentence: | "Mechanistically, honokiol suppressed H(2)O(2)-induced phosphorylation of ERK1/2, p38 mitogen-activated protein kinase (MAPK), JNK and Akt. Honokiol also inhibited H(2)O(2)-induced nuclear factor-kappaB (NF-kappaB)/p65 phosphorylation and translocation in HLE cells. These results demonstrate that honokiol suppresses H(2)O(2)-induced HLE cell apoptosis via interference with the MAPKs, Akt and NF-kappaB signaling, suggesting that honokiol might have a potential effect against cataract formation." |
Sequence & Structure:
MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MAPK8 | BENTAMAPIMOD | c-Jun N-terminal kinase, JNK inhibitor | 2 | Completed | endometriosis | ClinicalTrials |
| MAPK8 | TANZISERTIB | c-Jun N-terminal kinase 1 inhibitor | 2 | Terminated | idiopathic pulmonary fibrosis | ClinicalTrials |
| MAPK8 | TANZISERTIB | c-Jun N-terminal kinase 1 inhibitor | 2 | Terminated | lupus erythematosus | ClinicalTrials |
| MAPK8 | CC-401 | c-Jun N-terminal kinase 1 inhibitor | 1 | Terminated | myeloid leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| MAPK8-Tyr185 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | -0.707 |
| HGSC | 0.707 |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 185 | U | Pancreatic cancer | Phosphorylation | 37016317 |
| Y | 185 | U | Type 2 diabetes | Phosphorylation | 21931634 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
